Effective treatment for 5.5 million Americans with Alzheimer's disease (AD) is desperately needed, as this irreversible brain disorder is the third leading cause of death in people aged 65 or older, and the leadingcause of dementia. However, previous failed AD drug trials indicated that disease-modifying drugs need to be targeted to early-stages of AD to enable halting of the disease before significant damage has occurred. For thisearly-stage disease targeting therapeutic intervention, robust methods to detect early abnormal changes in the brain must be developed, highlighting an urgent need for a diagnostic biomarker for the early detection of AD pathology. Current AD biomarkers are mainly used at late-stage or for differential diagnosis of AD patients. Measurements of these biomarkers do not satisfy unmet clinical needs, as they do not offer effective diagnosis at the pre-symptomatic stage of disease progression (pre-symptomatic AD to Mild Cognitive Impairment (MCI)stage of AD). One potential biomarker that might facilitate early detection of early-stage pathology and disease progression in high-risk populations who could potentially develop AD is aberrant cyclin-dependent kinase 5(aCdk5), which is generated during neurotoxic stress conditions. Previous studies demonstrated that induction of aCdk5 activity occurs prior to AD pathology. Aestas's diagnostic neuroimaging candidate targets disease-specific aCdk5, without interfering with normal functions. aCdk5 is considered a "unifying upstream" event in the development of AD pathologies. Aestas Pharma will develop an aCdk5 PET Imaging Agent, AP-251-X, as a first-in-class non-invasive biomarker detection agent for the early detection of AD pathology. This diagnostic approach has the potential to facilitate detecting AD pathology earlier than existing biomarkers and may also beused alongside a Cdk5-based therapeutics or other drug candidates as a diagnostic imaging agent to measure the target engagement or efficacy of the therapeutics and monitor outcomes. AP-251-X links a radiotracer for neuroimaging to a small, highly specific a Cdk5 inhibitory peptide (AP-PEP31) exclusively licensed from NIH. Aim1 is to develop radio ligands that are suitable as diagnostic imaging agents. We will apply these compounds toPET neuroimaging in both male and female AD model mouse brains for early detection of pathology. Aim 2 is to test the feasibility of a lead radio ligand as a tool to measure the AD treatment outcome in the AD model. We will treat symptomatic and asymptomatic AD mice with an a Cdk5 blocker drug and our radioligand as a tool to determine the reversal of AD-like pathologies. Successful completion of SBIR Phase I studies will result in Aestas Pharma developing an a Cdk5-selective diagnostic for early detection of Alzheimer's disease in a mouse model.In the next several years, we plan to commercialize the agent for screening high-risk populations and for monitoring AD treatments with a Cdk5-based therapeutics or other AD drugs. A new method to detect pathologic changes in the brain for early detection of Alzheimer's Disease pathology is desperately needed for early diagnosis. Aberrant cyclin-dependent kinase5 (aCdk5) is a unifying upstream event in the development of AD pathology. Aestas Pharma will develop radio ligands to detect aCdk5 that are suitable as diagnostic imaging agents and treatment outcome measurements. Aftercare ; After Care ; After-Treatment ; post treatment ; Alzheimer's Disease ; AD dementia ; Alzheimer ; Alzheimer Type Dementia ; Alzheimer disease ; Alzheimer sclerosis ; Alzheimer syndrome ; Alzheimer's ; Alzheimer's disease dementia ; Alzheimers Dementia ; Alzheimers disease ; Primary Senile Degenerative Dementia ; dementia of the Alzheimer type ; primary degenerative dementia ; senile dementia of the Alzheimer type ; Amyloid ; Amyloid Substance ; Blood - brain barrier anatomy ; Blood-Brain Barrier ; Hemato-Encephalic Barrier ; bloodbrain barrier ; Brain ; Brain Nervous System ; Encephalon ; Brain Diseases ; Brain Disorders ; Encephalon Diseases ; Intracranial CNS Disorders ; Intracranial Central Nervous System Disorders ; Calpain ; Ca2+-Activated Protease ; Calcium-Activated Neutral Protease ; Calcium-Activated Neutral Proteinase ; Calcium-Activated Protease ; Calcium-Dependent Neutral Protease ; Calcium-Dependent Neutral Proteinase ; Desminase ; Papain-Like Cysteine Protease ; Cause of Death ; Diagnosis ; Differential Diagnosis ; Diagnostic Imaging ; Disease ; Disorder ; Pharmaceutical Preparations ; Drugs ; Medication ; Pharmaceutic Preparations ; drug/agent ; Female ; Lead ; Pb element ; heavy metal Pb ; heavy metal lead ; male ; Methods ; Study models ; Mus ; Mice ; Mice Mammals ; Murine ; United States National Institutes of Health ; NIH ; National Institutes of Health ; Neurons ; Nerve Cells ; Nerve Unit ; Neural Cell ; Neurocyte ; neuronal ; Pathology ; Peptides ; Plasma ; Blood Plasma ; Plasma Serum ; Reticuloendothelial System, Serum, Plasma ; Positron-Emission Tomography ; PET ; PET Scan ; PET imaging ; PETSCAN ; PETT ; Positron Emission Tomography Medical Imaging ; Positron Emission Tomography Scan ; Rad.-PET ; positron emission tomographic (PET) imaging ; positron emission tomographic imaging ; positron emitting tomography ; Proteins ; Stress ; Testing ; calpain inhibitor ; CANP-I ; calcium-activated neutral protease inhibitor ; Measures ; Neurofibrillary Tangles ; neurofibrillary degeneration ; neurofibrillary lesion ; neurofibrillary pathology ; tangle ; tau Proteins ; MT-bound tau ; microtubule bound tau ; microtubule-bound tau ; tau ; tau factor ; Ï Proteins ; Treatment outcome ; Guidelines ; Prosthesis ; Prosthetic device ; Prosthetics ; base ; Clinical ; Phase ; Series ; Link ; Failure ; Memory impairment ; Memory Deficit ; memory dysfunction ; nonhuman primate ; non-human primate ; Measurement ; Disease Progression ; Patient Recruitments ; participant recruitment ; uptake ; Cyclin-Dependent Kinase 5 ; Cell Division Kinase 5 ; Cell Division Protein Kinase 5 ; Serine/Threonine-Protein Kinase PSSALRE ; TPKII Catalytic Subunit ; Tau Protein Kinase II Catalytic Subunit ; cdc2-related kinase PSSALRE ; tau-1 ; p-tau ; p-Ï ; phospho-tau ; phospho-Ï ; phosphorylated tau ; Molecular Abnormality ; Chromosomal, Gene, or Protein Abnormality ; Cytogenetic or Molecular Genetic Abnormality ; Genetic Abnormality ; molecular aberrations ; Therapeutic ; Metabolic ; cleaved ; Cleaved cell ; tool ; Diagnostic ; Hour ; Event ; Amentia ; Dementia ; age group ; American ; early detection ; Early Diagnosis ; longitudinal positron emission tomography ; radiolabel ; radiotracer ; nerve cell death ; nerve cell loss ; neuron cell death ; neuron cell loss ; neuron death ; neuronal cell death ; neuronal cell loss ; neuronal death ; neuronal loss ; neuron loss ; radioligand ; Toxicities ; Toxic effect ; neuro-imaging ; neuroimaging ; intervention therapy ; Therapeutic Intervention ; 18-FDG ; 18F- FDG ; 18FDG ; 2 Fluoro 2 deoxy D glucose ; 2-Fluoro-2-deoxyglucose ; fluorodeoxyglucose ; Intervention Strategies ; interventional strategy ; Intervention ; Symptoms ; Detection ; in vitro Assay ; in vivo ; Rodent Model ; Small Business Innovation Research Grant ; SBIR ; Small Business Innovation Research ; Translational Research ; Translational Science ; translation research ; Pathologic ; Monitor ; follow-up ; Active Follow-up ; active followup ; follow up ; followed up ; followup ; Development ; developmental ; Pathway interactions ; pathway ; astrogliosis ; neuroinflammation ; neuroinflammatory ; Biodistribution ; Treatment Efficacy ; intervention efficacy ; therapeutic efficacy ; therapy efficacy ; Outcome ; aged ; Impairment ; neurotoxic ; Early treatment ; early therapy ; Alzheimer disease detection ; AD detection ; Alzheimer's detection ; Alzheimer like pathology ; Alzheimer's disease like pathology ; mouse model ; murine model ; Alzheimer's disease model ; AD model ; alzheimer model ; effective therapy ; effective treatment ; Biological Markers ; bio-markers ; biologic marker ; biomarker ; drug candidate ; phase 1 study ; Phase I Study ; screening ; mild cognitive impairment ; mild cognitive disorder ; targeted treatment ; targeted drug therapy ; targeted drug treatments ; targeted therapeutic ; targeted therapeutic agents ; targeted therapy ; imaging agent ; Alzheimer's disease pathology ; AD pathology ; Alzheimer's pathology ; potential biomarker ; potential biological marker ; diagnostic biomarker ; diagnostic marker ; early detection biomarkers ; early biomarkers ; early detection markers ; high risk population ; high risk group ; Injections ; first-in-human ; first in man ; Alzheimer's disease biomarker ; Alzheimer's biomarker ; Alzheimer's disease biological marker ; Alzheimer's biological marker ; blood-brain barrier penetration ; BBB penetration ; bloodbrain barrier penetration ; treatment comparison ; compare treatment ; Alzheimer's disease diagnosis ; Alzheimer's diagnosis ; asymptomatic Alzheimer's disease ; asymptomatic Alzheimer's ; Alzheimer's disease patient ; Alzheimer's patient ; feasibility testing ;
